U.S. Restricts Trade With Chinese Genomics Giant BGI Over Forced Labor Allegations

The United States has imposed new trade restrictions on BGI Group, one of China's largest genomics companies, blocking shipments into the country. U.S. officials allege that BGI is linked to forced labor and the abuse of minority groups, particularly Uyghurs in Xinjiang. The action, announced by the Department of Homeland Security, adds BGI to the Uyghur Forced Labor Prevention Act Entity List, making it the first major Chinese life sciences firm to face such a ban. This move signals a significant escalation in Washington's efforts to pressure Beijing over human rights, extending beyond traditional sectors like cotton and solar panels into the biotech industry. BGI, known for its gene sequencing and COVID-19 testing kits, has denied the allegations, calling them unfounded. However, the restriction could disrupt global supply chains for genetic research and diagnostics, as BGI supplies tools to labs worldwide. For U.S. researchers and healthcare providers, the ban means finding alternative suppliers, potentially raising costs and delaying projects. The decision also reflects growing scrutiny of Chinese companies with ties to state security apparatus, as Washington seeks to decouple critical technologies from Beijing. Going forward, other biotech firms with operations in Xinjiang may face similar scrutiny, reshaping the global genomics market and intensifying the U.S.-China tech rivalry.